Company Encyclopedia
View More
name
Sophia Genetics SA
SOPH.US
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is based in Rolle, Switzerland.
65.58 B
SOPH.USMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
Health Care TechnologyIndustry
Industry Ranking18/45
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-86.09%E
    • Profit Margin-102.29%E
    • Gross Margin66.32%A
  • Growth ScoreC
    • Revenue YoY13.66%B
    • Net Profit YoY-5.02%C
    • Total Assets YoY-7.97%E
    • Net Assets YoY-46.53%E
  • Cash ScoreC
    • Cash Flow Margin-97.76%D
    • OCF YoY13.66%B
  • Operating ScoreC
    • Turnover0.43C
  • Debt ScoreD
    • Gearing Ratio62.87%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    VP Menu Files To Sell 608 Of SOPHiA GENETICS SA [SOPH]

    Menu Philippe, VP of SOPHiA GENETICS SA, filed a Form 144 with the SEC to sell 608 shares on December 19, 2025, through Morgan Stanley Smith Barney LLC, under a 10b5-1 plan. This filing allows the sale within 90 days.

    Reuters·
    US
    SOPH
    -2.54%
    Reuters·
    US
    SOPH
    -2.54%

    Sophia Genetics Expands Precision Oncology Research with Cambridge Lab Integration

    Sophia Genetics SA is expanding its precision oncology research by integrating the East Genomics laboratory in Cambridge into its network. The lab will use the SOPHiA DDM™ Platform for cancer profiling, focusing on solid tumour samples. This move aims to enhance the understanding of complex cancers for patients in the East of England.

    Reuters·
    US
    SOPH
    -2.54%
    Reuters·
    US
    SOPH
    -2.54%

    Sophia Genetics SA Partners with Tyrolpath to Launch MSK-IMPACT Flex in Austria

    Sophia Genetics SA has partnered with Tyrolpath to introduce MSK-IMPACT Flex in Austria, marking the first adoption of this advanced oncology solution in the country. This collaboration aims to enhance cancer testing and precision oncology by leveraging the SOPHiA DDM Platform for comprehensive genomic profiling of solid tumors, addressing the need for actionable genomic insights in cancer care.

    Reuters·
    US
    SOPH
    -2.54%
    Reuters·
    US
    SOPH
    -2.54%

    Sophia Genetics SA reports Q3 revenue of $19.5 million

    Sophia Genetics SA reported Q3 revenue of $19.5 million for the three months ending September 30, 2025, an increase from $15.9 million in Q3 2024. For the nine months, revenue reached $55.6 million, up from $47.4 million in 2024. Gross profit for Q3 was $12.9 million, compared to $10.7 million a year earlier. However, the total comprehensive loss for Q3 2025 was $20.2 million, up from a loss of $11.6 million in Q3 2024. The company operates in a single segment with no significant changes in financial risk management.

    Reuters·
    US
    SOPH
    -2.54%
    Reuters·
    US
    SOPH
    -2.54%

    SOPHiA GENETICS SA expected to post a loss of 24 cents a share - Earnings Preview

    SOPHiA GENETICS SA is expected to report a quarterly revenue increase of 14.3% to $18.125 million for the period ending September 30, 2025, despite an anticipated loss of 24 cents per share. The average analyst rating is "strong buy" with a median 12-month price target of $6.00, reflecting a 13.5% upside from the last closing price of $5.19. Recent performance shows mixed results, with several earnings misses and beats in previous quarters.

    Reuters·
    US
    SOPH
    -2.54%
    Reuters·
    US
    SOPH
    -2.54%
    © 2025 Longbridge｜Disclaimer